R Rocket Pharmaceuticals
| Market Cap | $385.42M |
| P/E Ratio | — |
| Forward P/E | -2.65 |
| Dividend Yield | — |
| Beta | 0.57 |
| 52W Range | $2.33 - $8.01 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Lee Ainslie Maverick Capital | 0.09% | $8.82M | 2,513,110 | Reduce 70.32% |
Insider Trading
| Insider Name of the company insider who made the trade 24 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Shah GauravCEO | Sale | 5,990 | $3.34 | $19.99K | 18 Feb 2026 | 20 Feb 2026 |
| Wilson MartinGeneral Counsel | Sale | 1,376 | $3.34 | $4.59K | 18 Feb 2026 | 20 Feb 2026 |
| Militello JohnSee Remarks | Sale | 1,157 | $3.34 | $3.86K | 18 Feb 2026 | 20 Feb 2026 |
| Wilson MartinGeneral Counsel | Sale | 12,253 | $3.31 | $40.58K | 13 Feb 2026 | 18 Feb 2026 |
| Shah GauravCEO | Sale | 12,279 | $3.31 | $40.67K | 13 Feb 2026 | 18 Feb 2026 |
| Militello JohnSee Remarks | Sale | 3,726 | $3.31 | $12.34K | 13 Feb 2026 | 18 Feb 2026 |
| Bjork Elisabeth | Buy | 10,000 | $3.44 | $34.40K | 02 Jan 2026 | 06 Jan 2026 |
| Elisabeth BjorkDirector | Buy | 10,000 | $3.44 | $34.40K | 02 Jan 2026 | 06 Jan 2026 |
| Schwartz Jonathan DavidSee Remarks | Sale | 2,545 | $2.98 | $7.59K | 18 Nov 2025 | 20 Nov 2025 |
| Wilson MartinGeneral Counsel | Sale | 1,646 | $2.98 | $4.91K | 18 Nov 2025 | 20 Nov 2025 |
| Shah GauravCEO | Sale | 6,276 | $2.98 | $18.72K | 18 Nov 2025 | 20 Nov 2025 |
| Militello JohnSee Remarks | Sale | 1,086 | $2.98 | $3.24K | 18 Nov 2025 | 20 Nov 2025 |
| Gaurav ShahCEO | Sale | 6,276 | $2.98 | $18.72K | 18 Nov 2025 | 20 Nov 2025 |
| Jonathan David SchwartzChief Science & Gene Therapy Officer | Sale | 2,545 | $2.98 | $7.59K | 18 Nov 2025 | 20 Nov 2025 |
| Martin WilsonGeneral Counsel | Sale | 1,646 | $2.98 | $4.91K | 18 Nov 2025 | 20 Nov 2025 |
| John MilitelloVice President of Finance, Treasurer, Principal Accounting Officer | Sale | 1,086 | $2.98 | $3.24K | 18 Nov 2025 | 20 Nov 2025 |
| Militello JohnSee Remarks | Sale | 558 | $3.98 | $2.22K | 14 Oct 2025 | 16 Oct 2025 |
| Militello JohnSee Remarks | Sale | 3,005 | $3.97 | $11.93K | 14 Oct 2025 | 16 Oct 2025 |
| Militello JohnSee Remarks | Sale | 5,514 | $3.97 | $21.86K | 14 Oct 2025 | 16 Oct 2025 |
| Militello JohnSee Remarks | Sale | 19,841 | $3.96 | $78.57K | 14 Oct 2025 | 16 Oct 2025 |
| John MilitelloVice President of Finance, Treasurer, Principal Accounting Officer | Sale | 3,005 | $3.97 | $11.93K | 14 Oct 2025 | 16 Oct 2025 |
| John MilitelloVice President of Finance, Treasurer, Principal Accounting Officer | Sale | 19,841 | $3.96 | $78.57K | 14 Oct 2025 | 16 Oct 2025 |
| John MilitelloVice President of Finance, Treasurer, Principal Accounting Officer | Sale | 558 | $3.98 | $2.22K | 14 Oct 2025 | 16 Oct 2025 |
| John MilitelloVice President of Finance, Treasurer, Principal Accounting Officer | Sale | 5,514 | $3.97 | $21.86K | 14 Oct 2025 | 16 Oct 2025 |
Frequently Asked Questions
What is RCKT stock price today?
Rocket Pharmaceuticals (RCKT) is currently trading at $3.55. The stock has a 52-week range of $2.33 to $8.01 and a market capitalization of $385.42M.
Is RCKT a good stock to buy in 2026?
Rocket Pharmaceuticals has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of -36.2%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling RCKT stock?
There have been 24 insider transactions for RCKT in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has RCKT stock performed over the past year?
Rocket Pharmaceuticals (RCKT) has returned -36.2% over the past 12 months. The stock traded between $2.33 and $8.01 during this period, and is currently at $3.55.
Which hedge funds own RCKT (Rocket Pharmaceuticals)?
1 tracked hedge funds currently hold RCKT in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is RCKT's market cap and valuation?
Rocket Pharmaceuticals (RCKT) has a market capitalization of $385.42M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is RCKT's revenue and profitability?
Rocket Pharmaceuticals reported revenue of N/A with net income of N/A and a profit margin of N/A. The stock has a beta of 0.57.
What sector is RCKT in and who are its biggest institutional holders?
Rocket Pharmaceuticals (RCKT) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.